Jefferies Financial Group Inc. Purchases New Position in DaVita Inc. $DVA

Jefferies Financial Group Inc. purchased a new position in DaVita Inc. (NYSE:DVA) in the 2nd quarter, HoldingsChannel reports. The firm purchased 3,090 shares of the company’s stock, valued at approximately $687,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Berkshire Hathaway Inc bought a new position in shares of DaVita during the 2nd quarter valued at approximately $6,425,269,000. BlackRock Inc. purchased a new position in DaVita during the second quarter worth $547,520,000. Bank of America Corp DE bought a new position in DaVita during the second quarter valued at $145,057,000. Arrowstreet Capital Limited Partnership increased its position in DaVita by 114.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after acquiring an additional 636,191 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of DaVita in the second quarter valued at $101,127,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider directly owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. UBS Group lifted their price target on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Weiss Ratings raised shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. Truist Financial dropped their target price on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research report on Friday, August 7th. Finally, Raymond James Financial set a $220.00 target price on DaVita in a research note on Friday, August 7th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $221.75.

DaVita Trading Down 2.5%

Shares of DVA opened at $176.18 on Tuesday. The firm has a fifty day moving average price of $211.29 and a 200-day moving average price of $183.62. The firm has a market capitalization of $11.24 billion, a P/E ratio of 14.42, a P/E/G ratio of 0.47 and a beta of 0.88. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $247.49.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping the consensus estimate of $3.88 by $0.14. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Analysts predict that DaVita Inc. will post 14.57 earnings per share for the current year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.